Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity
Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity
The inside story of the race to develop Ozempic, and its potentially revolutionary impact on public health and culture.
A "cure" for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates hormones in the stomach, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries--from health care to fast food to fashion--and it has quickly made its creator, Denmark's Novo Nordisk, the most valuable company in Europe. But the impact of these drugs goes far beyond billion dollar profits; a true long-term cure for obesity could save 40% of American adults from dangerous preventable illnesses. And as their success continues to grow, one question looms in the minds of investors, healthcare workers and politicians: are they too good to be true?
PRP: 186.00 Lei
Acesta este Prețul Recomandat de Producător. Prețul de vânzare al produsului este afișat mai jos.
167.40Lei
167.40Lei
186.00 LeiLivrare in 2-4 saptamani
Descrierea produsului
The inside story of the race to develop Ozempic, and its potentially revolutionary impact on public health and culture.
A "cure" for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates hormones in the stomach, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries--from health care to fast food to fashion--and it has quickly made its creator, Denmark's Novo Nordisk, the most valuable company in Europe. But the impact of these drugs goes far beyond billion dollar profits; a true long-term cure for obesity could save 40% of American adults from dangerous preventable illnesses. And as their success continues to grow, one question looms in the minds of investors, healthcare workers and politicians: are they too good to be true?
Detaliile produsului